Befejeződött2. fázis
A trial to compare efficacy and safety of follitropin delta versus placebo (inactive treatment) in the treatment of men with idiopathic infertility (unexplained reduction of semen quality).
A legfontosabb adatok
- Ki végzi
- Ferring Pharmaceuticals A/S
- Hol
- Belgium, Dánia, Németország, Olaszország, Spanyolország és Svédország10 helyszín, 6 országbanVálassz országot a helyszínekhez
- Állapot
- Befejeződött
- Fázis
- 2. fázis
- Résztvevők
- 197 fő vett részt
- Kezdés
- 2023. jan. 12.
- Befejezés
- 2024. okt. 23.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2024. október 16.
Ki vehet részt
- Életkor
- 18 év – 64 év
- Nem
- Csak férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 22 feltétel megnézéseKevesebb
Ki vehet részt
- History of infertility for 12-60 months with current partner at randomisation
- Agree to provide information on female partner's positive urine pregnancy test(s) and documentation of ultrasound(s), delivery, and neonatal/infant health
- Current partner fulfilling the criteria below: a) Pre-menopausal woman between the ages of 18 and 35 years. b) Regular menstrual cycles of 21-35 days. c) No history or current condition of pelvic inflammatory disease, endometriosis stage II-IV by definite or empirical diagnosis, or tubal ligation. d) Agree not to obtain infertility treatment outside of this trial for 9 months from randomisation of male subject
- Men between the ages of 18 and 50 years
- Total sperm count 5-39 million at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomisation
- Total sperm motility of ≥10% at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomisation
- Semen volume ≥1.4 mL at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomisation
- Serum follicle-stimulating hormone (FSH) levels of 1.5-8.0 IU/L (measured at central laboratory) at screening
- Serum luteinising hormone (LH) levels of 1.2-7.5 IU/L (measured at central laboratory) at screening
- Serum total testosterone levels of ≥300 ng/dL (equals ≥10.4 nmol/L; measured at central laboratory) at screening
- Agree to have regular intercourse with current female partner with the intent of spontaneous conception within 9 months from randomisation
Ki nem vehet részt
- Previous FSH treatment not leading to conception
- Administration of hormonal preparations, agents known to impair testicular function or affect sex hormone secretion, and known or suspected teratogens within 3 months prior to screening. Administration of anabolic steroids within 12 months prior to screening
- Past or current use of finasteride within 3 months prior to screening
- Any known uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders)
- Any history of anatomical disorder of the pituitary gland or testes
- Any known, clinically significant, systemic disease in addition to the trial indication that might negatively impact fertility
- Known history of cryptorchidism, testicular torsion, or orchitis
- Current or past treatment of urogenital (kidney, bladder, testicular, or prostate) cancer as well as history of chemo- or radiotherapy that can have impact on testes
- Any structural abnormalities of the vas deferens (unilateral or bilateral) at screening
- Known history or presence of clinical varicocele (subclinical and Grade 1 varicocele are acceptable)
- Known abnormal karyotype (including Y-chromosome microdeletion)
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
6 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
To investigate the effect of FE 999049 treatment of men with idiopathic infertility on the chance of spontaneous pregnancy in their female partners.
Adatok és források
- Regiszteradat
- Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of FE 999049 for treatment of men with idiopathic infertility
- A regiszteradat frissítve
- 2024. október 16.